osimertinib,tepotinib
astrazeneca,merck
['insight-2', 'osimertinib', 'tepotinib']
 first results of insight-2 trial #esmo22. combo of tepotinib and osimertinib is feasible and associated with 54.5% orr (in fish + tbx patients) in metamp patients displaying progression under 1l osimertinib. 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??